Your session is about to expire
← Back to Search
Dihydroergotamine for Migraine (ASCEND Trial)
ASCEND Trial Summary
This trial will study the safety and tolerability of a new drug, STS101, for the acute treatment of migraines. The trial will last 12 months and will be conducted at multiple centers.
- Migraine
ASCEND Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowASCEND Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 482 Patients • NCT04406649ASCEND Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How does Dihydroergotamine compare to other drugs in its class?
"There is currently one Dihydroergotamine study in Phase 3 with 45 clinical trial sites around the world, mostly concentrated in the state of California."
Are there any more patients needed to complete this clinical trial?
"This study has completed recruitment for patients. The trial was first posted on 9/14/2020 and was most recently edited on 8/5/2022. If you are exploring for other studies, there are currently 177 trials actively searching for patients with migraine and 1 studies for Dihydroergotamine actively searching for participants."
Are there specific inclusion criteria for this research project?
"This study will be conducted on 482 individuals that suffer from migraines and meet the age criteria of being between 18-65. It's worth mentioning that migraineurs of both genders are eligible for this trial, so long as they have had a history of migraines (with or without aura) for at least one year."
How many test subjects are included in this clinical trial?
"This clinical trial is not currently looking for new participants. However, this study was last updated on August 5th, 2022 and might open up recruitment in the future. Alternatively, there are presently 177 clinical trials actively searching for participants with migraine and 1 trials for Dihydroergotamine that are enrolling patients right now."
Could you provide a number for how many sites are participating in this clinical trial?
"This clinical trial is based out of Clin Cloud in Maitland, Florida, Multi-Specialty Research Associates in Lake City, Louisiana and Delricht Research in Prairieville, Massachusetts with 31 other sites participating."
Has Dihydroergotamine received regulatory approval from the FDA?
"Dihydroergotamine received a safety score of 3 because there is both evidence of efficacy and multiple trials supporting its safety."
Could you tell me if this research is only applicable to those over 60 years old?
"According to the inclusion criteria laid out by this trial, patients must be aged between 18-65. There are 32 studies available for people who fall below the age bracket and 123 trials for those over 65."
Has a trial like this been conducted before?
"Dihydroergotamine has been investigated in clinical trials since 2020, when Satsuma Pharmaceuticals, Inc. first sponsored a study of the drug. This initial trial involved 482 patients. After this Phase 3 approval process was completed in 2020, only one active study involving Dihydroergotamine remains; it is also sponsored by Satsuma Pharmaceuticals, Inc.."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger